Annexon, Inc. Common Stock (ANNX) Stock Price

ANNXStock
$3.41+7.57%52W
Market Cap$646.46M
P/E—
PEG Ratio—
Div yield—
Beta1.41

ANNX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-51.11%
Price vs S&P 500 (4W)-17.87%
VGM Score39.77

ANNX Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.24-$0.28-15.17%(-$0.04)
Q1 2026-$0.30-$0.23+24.01%(+$0.07)
Q4 2025-$0.32-$0.28+11.20%(+$0.04)
Q3 2025-$0.34-$0.37-7.94%(-$0.03)
Q2 2025-$0.36-$0.34+5.96%(+$0.02)

ANNX Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.12
4.12
4.00
4.06

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
ANNXAnnexon, Inc. Common Stock
——D————$3.41
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Annexon, Inc. Common Stock

Annexon Inc is a clinical-stage biopharmaceutical company developing C1q inhibitors to treat complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. The company's platform technology targets the classical complement pathway across multiple disease areas affecting the body, brain, and eye. Its pipeline includes product candidates ANX005, ANX007, ANX009, and ANX1502 in development.